2025-08-01 - Analysis Report
Okay, here's an analysis of Transmedics Group Inc. (TMDX) based on the provided data. I will present the analysis in English with numerical data and concise explanations.

## TMDX (Transmedics Group Inc.) Stock Analysis

**Company Overview:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation systems for transplantation.

**1. Performance vs. S&P 500 (VOO)**

*   **TMDX Cumulative Return:** 233.67%
*   **VOO (S&P 500) Cumulative Return:** 72.10%
*   **Absolute Difference (Current):** 155.4%
*   **Range-Adjusted Difference:** 60.9 (Indicates TMDX's outperformance is in the upper half of its historical range relative to VOO)

**Alpha/Beta Analysis:**

| Year       | CAGR      | MDD   | Alpha    | Beta | Cap(B) |
|------------|-----------|-------|----------|------|--------|
| 2019-2021  | -4.0%     | 63.4% | -52.0%   | 0.1  | 0.7    |
| 2020-2022  | 140.0%    | 68.3% | 133.0%   | 0.2  | 2.1    |
| 2021-2023  | 95.0%     | 69.4% | 75.0%    | 0.4  | 2.7    |
| 2022-2024  | 147.0%    | 82.8% | 120.0%   | 0.4  | 2.1    |
| 2023-2025  | 115.0%    | 82.8% | 67.0%    | 0.6  | 4.0    |

**Analysis:**

*   TMDX has significantly outperformed the S&P 500 over the period.
*   The high range-adjusted difference suggests this outperformance is substantial relative to its past behavior.
*   The Alpha/Beta analysis reveals the stock's risk-adjusted return characteristics. A positive alpha indicates that the investment has outperformed its benchmark index on a risk-adjusted basis.  Beta values generally greater than 1 indicates that the stock is more volatile than the S&P 500. High volatility and sensitivity to market movements.
*   CAGR indicates substantial growth potential, but accompanied by significant drawdown risk (MDD).
*   The increasing Cap(B) value suggests growing market capitalization and investor interest.

**2. Recent Stock Price Movement**

*   **Current Price:** $118.97
*   **Last Market Data:**
    *   Price: $118.97
    *   Previous Close: $107.70
    *   Change: $10.46
*   **5-Day Moving Average:** $108.97
*   **20-Day Moving Average:** $114.14
*   **60-Day Moving Average:** $122.41

**Analysis:**

*   The stock price has significantly increased compared to the previous close, indicating a strong positive move.
*   The 5-day moving average is below the 20-day moving average, which is below the 60-day moving average. This suggests a short-term upward trend, but it's important to monitor if the trend continues to strengthen or if the stock price retraces.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 57.08 (Neutral)
*   **PPO:** 0.30 (Neutral)
*   **Hybrid Signal:** Cash_7%_Buy 90% of cash (1401 shares - Safe - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** -1.2 (Short-term decline)
*   **Expected Return:** 62.5% (Long-term, relative to S&P 500)

**Analysis:**

*   The low MRI suggests a relatively stable market environment for the stock.
*   RSI and PPO are at neutral levels, indicating no immediate overbought or oversold conditions.
*   The "Hybrid Signal" suggests a buy recommendation, allocating most available cash to purchase shares.
*   The negative "Delta_Previous_Relative_Divergence" indicates a recent relative underperformance compared to its historical relationship with the S&P 500.
*   The high expected return is very positive, indicating significant long-term growth potential compared to the S&P 500.
*   The large price change from previous close reflects a significant event impacting the stock. This needs further investigation (see news below).

**4. Recent News & Significant Events**

*   **2025-07-29:** Major business developments, regulatory changes, or market events impacting TMDX.
*   **2025-07-31:** Analysts discussing TMDX's recent performance and outlook within the context of industry trends and global economic factors.
*   **2025-08-01:** Notable volatility in TMDX's stock influenced by recent news, earnings reports, or executive actions.
*   **2025-07-30:** Market experts highlighting risks and opportunities for TMDX, advising investors to monitor recent news and company announcements.

**Analysis:**

*   Recent news points to potential catalysts driving the stock's movement, including business developments, analyst opinions, and market volatility.  Investors should carefully examine specific news releases and company announcements for details.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 예상 EPS |
|------------|------|----------|
| 2025-07-30 | 0.92 | 0.48     |
| 2025-05-08 | 0.70 | 0.29     |
| 2025-02-27 | 0.19 | 0.22     |
| 2024-10-28 | 0.12 | 0.29     |
| 2024-07-31 | 0.35 | 0.21     |

**Analysis:**

*   Transmedics Group Inc. has consistently exceeded EPS estimates in recent quarters, suggesting strong financial performance. The significant outperformance in the most recent quarter (2025-07-30) likely contributed to the recent price surge.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.16B  | 61.38%        |
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-06-30 | $0.32B  | 10.97%  |
| 2025-03-31 | $0.27B  | 9.64%   |
| 2024-12-31 | $0.23B  | 3.00%   |
| 2024-09-30 | $0.21B  | 2.01%   |
| 2024-06-30 | $0.19B  | 6.42%   |

**Analysis:**

*   Revenue is consistently increasing, indicating strong growth in the company's sales.
*   The profit margin is very high, suggesting efficient operations and pricing power.
*   Equity is increasing, indicating a growing asset base.
*   ROE (Return on Equity) has shown considerable growth, reflecting increased profitability relative to shareholder equity.

**7. Overall Summary**

Transmedics Group Inc. (TMDX) shows strong signs of growth and outperformance:

*   **Significant Outperformance:** The stock has significantly outperformed the S&P 500.
*   **Strong Financials:** Revenue, profit margins, and equity are increasing. The company is consistently beating EPS estimates.
*   **Positive Outlook:** High expected return.
*   **Recent Volatility:** The recent price surge and news indicate potential catalysts and require careful monitoring.

**Conclusion:**

TMDX presents an interesting investment opportunity with high growth potential. However, investors should be aware of the stock's volatility and carefully monitor news and company announcements. The recent price surge warrants further investigation to understand its drivers and sustainability. Overall, the data suggests a bullish outlook for TMDX, but due diligence is critical.
